Journal
REVIEWS IN CARDIOVASCULAR MEDICINE
Volume 22, Issue 4, Pages 1589-1594Publisher
IMR PRESS
DOI: 10.31083/j.rcm2204164
Keywords
Extracorporeal membrane oxygenation; Extracorporeal cardiopulmonary resus-citation; Anticoagulation; Activated clotting time; Complication; Discharge survival
Categories
Funding
- Korea University [K1924931]
Ask authors/readers for more resources
This study investigated the impact of a lower target ACT during ECMO on safety and outcomes, finding that it did not increase the thromboembolic risk compared to a conventional ACT target. Clinicians may consider using a lower ACT target for anticoagulation in some patients with careful assessment and close monitoring. Further prospective trials are needed to validate these results.
Optimal anticoagulation is critical for successful extracorporeal membrane oxygenation (ECMO) to counterbalance the activation of the coagulation system initiated by the blood-biosurface reaction and mechanical stresses. Systemic anticoagulation is achieved mainly with unfractionated heparin (UFH). Activated clotting time (ACT) is a widely used laboratory parameter to monitor anticoagulation. The therapeutic range of ACT is 180-220 s. We investigated the effect of a lower target ACT (<150 s) during ECMO on safety and outcomes and compared it with those of a conventional target ACT (180- 200 s). In this single-center, retrospective study, we reviewed 72 adult patients treated with ECMO from March 2017 to October 2019. We included 43 patients after applying the exclusion criteria and divided them into the low ACT group (<150 s, n =14, 32.6%) and conventional ACT group (>= 150 s, n = 29, 67.4%). There was no difference in the successful weaning from ECMO support (50% vs. 62.1%, p = 0.452) and discharge (50% vs. 41.4%, p = 0.594) rates between the groups. One patient in the conventional ACT group had intracranial hemorrhage. There was one thromboembolic complication case with an intra-circuit thrombus. To date, anticoagulation remains a challenge during ECMO. Our results suggest that a lower target ACT does not necessarily increase the thromboembolic risk during ECMO management. Clinicians may consider anticoagulation with lower ACT target for some patients with careful assessment and close monitoring. Further prospective trials are warranted to validate these results.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available